Annovis Announces Two Presentations at the CTAD 2025 Conference

Core Insights - Annovis Bio, Inc. is a late-stage clinical drug platform company focused on developing therapies for neurodegenerative diseases, specifically Alzheimer's disease (AD) and Parkinson's disease (PD) [1][5] Group 1: Conference Presentations - Annovis will present at the 18 Clinical Trials on Alzheimer's Disease (CTAD) conference from December 1-4, 2025, in San Diego, California [1] - The presentations will emphasize progress in Alzheimer's and Parkinson's programs, particularly recent biomarker data that supports the potential disease-modifying activity of the drug buntanetap [2] Group 2: Key Findings and Statements - Maria Maccecchini, Ph.D., President and CEO of Annovis, expressed optimism about sharing findings on biomarkers and cognition, indicating that the data suggests buntanetap could address the root causes of cognitive decline [4] - The biomarker data reinforces the efficacy of buntanetap observed in earlier studies and provides a clearer path for developing effective treatments for patients in need [4] Group 3: Presentation Details - Presentation 1 will focus on "Amyloid co-pathology and cognitive decline in buntanetap-treated Parkinson's disease dementia patients," presented by Cheng Fang, Ph.D., Senior VP, Research & Development [8] - Presentation 2 will cover a "Double 6/18-month Phase 3 study to reproduce symptomatic and potentially show disease-modifying efficacy of buntanetap in treating Alzheimer's disease," presented by Maria Maccecchini, Ph.D., President and CEO [8]